Hematologic Oncology | Specialty

Burden of CMV Infection in HSCT Patients

January 18th 2018

FDA Grants Tisagenlecleucel Priority Review for DLBCL

January 17th 2018

The FDA has granted a priority review to the CAR T-cell therapy tisagenlecleucel for adult patients with relapsed/refractory DLBCL who are ineligible for or relapse after autologous stem cell transplant.

FDA Approves Arsenic Trioxide for Promyelocytic Leukemia

January 16th 2018

The FDA has approved arsenic trioxide (Trisenox) in combination with the all-trans retinoic acid agent tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia with the t(15;17) translocation or PML-RARA gene expression.

Considerations for Treating ITP in the Future

January 15th 2018

Potential Role of Syk Inhibitors in ITP

January 15th 2018

Splenectomy Versus Other Therapy in ITP

January 15th 2018

Immunosuppressive Therapy in ITP

January 15th 2018

TPO Receptor Agonists: Treatment Considerations

January 15th 2018

TPO Receptor Agonists in ITP

January 15th 2018

Treatment Guidelines for Relapsed/Refractory ITP

January 15th 2018

Clinical Management of Corticosteroids in ITP

January 15th 2018

Aggressive Treatment for Managing ITP

January 15th 2018

Upfront Use of Corticosteroids in ITP

January 15th 2018

Initiating Therapy in ITP

January 15th 2018

Counseling Patients on Goals of Therapy in ITP

January 15th 2018

Diagnosing Idiopathic Thrombocytopenia Purpura

January 15th 2018

Understanding the Pathophysiology of ITP

January 15th 2018

Axi-Cel Plus Atezolizumab Active, Safe in DLBCL

January 13th 2018

The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.

The Role of Transplant and Future of CLL

January 12th 2018

Other Promising Strategies in CLL

January 12th 2018